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Identity 
Note: Infant or congenital leukaemias are defined by a 
diagnosis within either the first month, the first year, or 
the first two years of life, according to different 
workers; recent data have shown that patients, 
diagnosed to have a leukaemia at age 5 mths and 2 
years, already had a MLL-AF4 fusion gene in their 
neonatal blood spots/Guthrie cards. 
Infant leukaemias have been suspected to have an 
environmental component:  
1- some of the leukaemias known to be often related to 
genotoxic exposure, such as the 11q23 leukaemias and 
the t(8;16) leukaemia, may also be found in infants;  
2- there has been a significant increase in infant acute 
leukaemias incidence of around 2.5% per year for 15 
years, suggesting the presence of an environmental 
factor;  
3- infants with leukaemia (excluding Down syndrome 
cases) have more congenital anomalies (heart defects, 
digestive tract anomalies, mental delay). 
They may be myelodysplasia or acute non lymphocytic 
leukaemia (M4 or M5 mainly) in 1/2 to 2/3 of cases, or 
B-cell acute lymphocytic leukaemia (CD19+ or 
CD10+) in the remaining cases. 
Sex ratio is balanced, both in ANLL and in ALL cases. 
Frequent CNS involvement; WBC is often high, 
whatever the chromosome anomaly is; skin infiltrations 
(leukaemia cutis) may occur. 
11q23 is found involved in 1/3 to 1/2 of cases (t(4;11), 
t(9;11), and t(11;19) representing nearly 1/10 of cases 
each). 
See also 11q23 rearrangements in childhood acute 
lymphoblastic leukemia: Clinical aspects. 
4 year event free survival in infants ALL is 1/3 and 
median event free survival (EFS) is 1 year. 
In infants aged less than a month, 6 months survival is 
only 1/3, both in ANLL and in ALL. 
As the prognosis is most often very poor, bone marrow 
transplantation is indicated, apart in infant leukemia of 
the Down syndrome patient, were the prognosis is 
good. 




They most often exhibit a normal karyotype or a 
monosomy 7. 
Etiology 
Exhibit a genetic background or is considered as 
idiopathic. 
Epidemiology 
Annual incidence: about 1 case per 106. 
Prognosis 
Has herein been calculated from 3 large studies (n=47): 
median survival was 31 mths; 6 year survival was 43%. 
Disease 
Down syndrome with M7. 
Note 
Down syndrome patients have been known for long to 
be at increased risk (10 to 30 fold) of both ALL and 
ANLL; ALL is similar in Down syndrome (DS) and in 
the general population, whereas ANLL in DS is most 
often a specific entity of acute megakaryoblastic 
leukaemia (M7-ANLL); at least 20% of leukaemias in 
DS are M7, and other cases of M7-ANLL may also be 
misclassified as undifferentiated leukaemias or as ALL; 
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therefore, the risk of M7 may well be 500 to 1000 times 
greater when the child has a DS; in other words, it may 
be that half of infants with M7 are DS ... and also that 
the risk of ALL in DS may not be as increased as 
previously claimed. 
Epidemiology 
M7 leukaemia in Down syndrome infants annual 
incidence: 0.2 case per 106; median age at diagnosis is 
22-23 mths. 
Clinics 
There is often a preceeding myelodysplasia, or history 
of transient leukemoid reaction (a disease of the 
megakaryocytic lineage). 
Prognosis 
M7-ANLL has proved to be of better prognosis when 
in DS, with a recent study on 65 DS patients with M7, 
showing a 4 yr event free survival of 73%. 
Disease 
11q23 abnormalities. 
Phenotype/cell stem origin 
M4 or M5 acute non lymphocytic leukaemia (ANLL) 
or CD19+ B-cell acute lymphocytic leukaemia (ALL). 
Epidemiology 
25% of 11q23 rearrangements cases are infant (<1 
year) cases; as much as 2/3 of cases of infant ALL 
leukaemias have been found in some studies to carry a 
11q23 rearrangement, especially in infants <6 mths old; 
a third to a half of infant ANLL cases also have a 
11q23 rearrangement; however, 11q23 leukaemias can 
also be seen in children and in adults. 
Clinics 
Organomegaly; frequent CNS involvement; high WBC. 
Prognosis 
Median survival of 1 year, and a 3 year event free 
survival of 13% in a study and a 4 year event free 
survival of 15% in another. 
- t(4;11)(q21;q23): CD19+ B-ALL; unbalanced sex 
ratio <4 yrs (1M/2F); infants (<1 year) accounting for 
1/3 of t(4;11) cases; annual incidence could be 0.3-0.5 
case per 106; prognosis: med EFS 7 mths; med survival 
29 mths; 3 year survival 40%; 3 year EFS: 30%; the 
gene involved in 4q21 is AF4.  
- t(9;11)(p23;q23): found in M5a or M4 ANLL; the 
rare ALL cases of t(9;11) are most often found in 
infants; infants cases (<1 year) account for 15% of all 
t(9;11) cases; med EFS: 1 year, 3 year EFS 20%; the 
gene involved in 9p22 is AF9. 
- t(10;11)(p12;q23): rare; M4 or M5 ANLL; ALL at 
times; infants represent 40% of cases; the gene 
involved in 10p12 is AF10.  
- t(11;19)(q23;p13.3): ALL, biphenotypic AL and M4 
or M5 ANLL; half cases of t(11;19)(q23;p13.3) are 
infant cases; a study on 40 cases showed that med 
survival was 5 mths, with a 2 year survival of 20% 
(unpublished observation); the gene involved in 
19p13.3 is ENL. 
- Other 11q23 rearrangements are rarely found in 
infants leukaemias. 
- In 11q23 sits MLL, which encodes a 431 kDa protein; 
contains two DNA binding motifs (a AT hook, and 
Zinc fingers), a DNA methyl transferase motif, a 
bromodomain; transcriptional regulatory factor; nuclear 
localisation; wide expression; homology with trithorax 
(drosophila); the fusion protein includes the N-term AT 
hook and DNA methyltransferase from MLL fused to 




Phenotype/cell stem origin 
M7 ANLL. 
Epidemiology 
39 cases so far described; 6 (perhaps much less); the 
only leukaemia (nearly) restricted to infant cases; 
median age is 4 mths. 
Clinics 
Organomegaly, bone marrow fibrosis; misdiagnosis of 
a solid tumour is frequent. 
Prognosis 
Remission is obtained in only half cases, median 
survival is 7 mths. 
Disease 
12p abnormalities 
Phenotype/cell stem origin 
B lineage ALL mainly (CD10+); M5 ANLL at times. 
Epidemiology 
At least 9 cases. 
Prognosis 
No sufficient data. 
Disease 
inv(16)(p13q22) 
Phenotype/cell stem origin 
M4 ANLL. 
Epidemiology 
At least 3 cases reported. 
Clinics 
High WBC, CNS involvement. 
Prognosis 
Is very poor so far (remission duration: 0, 2, 6 mths), in 
contrast with the usual inv(16) prognosis. 
Disease 
t(5;15)(p15;q11) 
Phenotype/cell stem origin 
B lineage ALL. 
Epidemiology 
5 known cases. 
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Unknown; CR in 5/5. 
Disease 
t(8;16)(p11;p13) 
Phenotype/cell stem origin 
M5/M4 ANLL. 
Epidemiology 
At least 3 cases. 
Prognosis 
Survival: 0.5 mth, 22 mths+, 24 mths+. 
Disease 
+19 and/or +21 
Phenotype/cell stem origin 
ANLL and ALL. 
Epidemiology 
At least 5 cases. 
Prognosis 
No survival data available. 
Disease 
Other chromosome rearrangements: +8 (solely or not), 
found in a few cases, del(6q), t(1;19)(q23;p13), and 
non recurring anomalies, found in at least one case 
each; finally, the kayotype has been found to be normal 
in a percentage of cases. 
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